Christian B Fulda
Europe Guide 2024
Band 3 : Life Sciences
Email address
[email protected]Contact number
+ 49.89.20.60.42.200Share profile
Band 3
About
Provided by Christian B Fulda
Career
Dr. Christian Fulda focuses his practice on the pharmaceutical, biotechnology, and medical device industries. Christian advises on strategic and transformative projects and matters, drawing on his extensive operational experience with the legal issues that these heavily regulated industries face. Christian has been the lead on transformative M&A deals, bet-the-company litigation, and disruptive technological developments. His particular focus is industry convergence, including digital health, and he routinely carries out multijurisdictional projects.
Chambers Review
Europe
Christian Fulda is well reputed for complex international patent and unfair competition disputes as well as pan-European regulatory reviews and compliance. He also advises on commercial matters and covers the regulatory aspects of M&A transactions in the life sciences sector. His client base consists of well-known German and multinational pharmaceuticals companies, life sciences start-ups and financial investors.
Strengths
Provided by Chambers
"It is a pleasure to work with Christian. He always knows the answer or will quickly put me in contact with somebody who does."
"Christian is a very experienced cooperate and business attorney. He has been extremely helpful to us."
"He has such a breadth of knowledge, will always get us an answer and we have been really impressed with him."
"He is very good at understanding how USA-centric companies view regulatory compliance risk in various European jurisdictions."
"It is a pleasure to work with Christian. He always knows the answer or will quickly put me in contact with somebody who does."
"Christian is a very experienced cooperate and business attorney. He has been extremely helpful to us."
"He has such a breadth of knowledge, will always get us an answer and we have been really impressed with him."
"He is very good at understanding how USA-centric companies view regulatory compliance risk in various European jurisdictions."